[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533147":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":36,"centralContacts":40,"locations":47,"responsibleParty":143,"collaborators":45,"id":145,"slug":45,"hasResults":146,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":45,"eligibilityCriteria":150,"healthyVolunteers":146,"sex":151,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":45,"studyType":157,"phases":158,"briefSummary":160,"conditions":161,"keywords":45,"overallStatus":50,"whyStopped":45,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":155},{"fullName":5,"class":6},"Alfasigma S.p.A.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Filgotinib Dose A","EXPERIMENTAL","Dose A of filgotinib mini-tablet for participants with bodyweight (BW) 15-\\\u003C25 kg",[13],"Drug: Filgotinib",{"label":15,"type":10,"description":16,"interventionNames":17},"Filgotinib Dose B","Dose B of filgotinib tablet for participants with BW ≥25-\\\u003C60 kg",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Filgotinib Dose C","Dose C of filgotinib tablet for participants with BW ≥60 kg",[13],[23,31],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Filgotinib","Film-coated mini-tablets administered orally once daily",[9],[29,30],"GS-6034","GLPG0634",{"type":24,"name":25,"description":32,"armGroupLabels":33,"otherNames":34},"Commercially developed film-coated tablet administered orally once daily",[15,19],[29,30,35],"Jyseleca",[37],{"name":38,"affiliation":5,"role":39},"Alfasigma Study Director","STUDY_DIRECTOR",[41],{"name":42,"role":43,"phone":44,"phoneExt":45,"email":46},"Pilar de la Torre","CONTACT","00800 7878 1345",null,"medicalinfo@alfasigma.com",[48,60,69,79,88,98,108,118,124,133],{"facility":49,"status":50,"city":51,"state":45,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":45},"CHU Amiens - Hopital Nord","RECRUITING","Amiens","80054","France",{"type":55,"coordinates":56},"Point",[57,58],2.3,49.9,{"lat":58,"lon":57},{"facility":61,"status":50,"city":62,"state":45,"zip":63,"country":53,"cosmosGeoPoint":64,"geoPoint":68,"contacts":45},"Bicêtre University Hospital","Le Kremlin-Bicêtre","94270",{"type":55,"coordinates":65},[66,67],2.36073,48.81471,{"lat":67,"lon":66},{"facility":70,"status":50,"city":71,"state":45,"zip":72,"country":73,"cosmosGeoPoint":74,"geoPoint":78,"contacts":45},"Children's university hospital Charité, Campus Virchow, SPZ","Berlin","13353","Germany",{"type":55,"coordinates":75},[76,77],13.41053,52.52437,{"lat":77,"lon":76},{"facility":80,"status":50,"city":81,"state":45,"zip":82,"country":73,"cosmosGeoPoint":83,"geoPoint":87,"contacts":45},"Hamburger Zentrum fur Kinder und Jugendrheumatologie","Hamburg","22081",{"type":55,"coordinates":84},[85,86],9.99302,53.55073,{"lat":86,"lon":85},{"facility":89,"status":90,"city":91,"state":45,"zip":92,"country":73,"cosmosGeoPoint":93,"geoPoint":97,"contacts":45},"Asklepios Klinik Sankt Augustin GmbH","NOT_YET_RECRUITING","Sankt Augustin","53757",{"type":55,"coordinates":94},[95,96],7.197,50.77538,{"lat":96,"lon":95},{"facility":99,"status":50,"city":100,"state":45,"zip":101,"country":102,"cosmosGeoPoint":103,"geoPoint":107,"contacts":45},"Malopolskie Badania Kliniczne","Krakow","30-002","Poland",{"type":55,"coordinates":104},[105,106],19.93658,50.06143,{"lat":106,"lon":105},{"facility":109,"status":50,"city":110,"state":45,"zip":111,"country":112,"cosmosGeoPoint":113,"geoPoint":117,"contacts":45},"Hospital Universitari Vall d'Hebron","Barcelona","08035","Spain",{"type":55,"coordinates":114},[115,116],2.15899,41.38879,{"lat":116,"lon":115},{"facility":119,"status":50,"city":110,"state":45,"zip":120,"country":112,"cosmosGeoPoint":121,"geoPoint":123,"contacts":45},"Hospital Sant Joan de Deu","08950",{"type":55,"coordinates":122},[115,116],{"lat":116,"lon":115},{"facility":125,"status":50,"city":126,"state":45,"zip":127,"country":112,"cosmosGeoPoint":128,"geoPoint":132,"contacts":45},"Hospital Universitari i Politecnic La Fe","Valencia","46026",{"type":55,"coordinates":129},[130,131],-0.37966,39.47391,{"lat":131,"lon":130},{"facility":134,"status":90,"city":135,"state":45,"zip":136,"country":137,"cosmosGeoPoint":138,"geoPoint":142,"contacts":45},"Great Ormond Street Hospital","London","WC1N 3JH","United Kingdom",{"type":55,"coordinates":139},[140,141],-0.12574,51.50853,{"lat":141,"lon":140},{"type":144,"investigatorFullName":45,"investigatorTitle":45,"investigatorAffiliation":45,"oldNameTitle":45,"oldOrganization":45},"SPONSOR","100533147",false,"NCT06222034","Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)","An Open-label, Multiple Dose, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Filgotinib in Children and Adolescents From 8 to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis","Key Inclusion Criteria:\n\n* Participant with a body mass index (BMI) within the 5th to 95th percentiles for the age and gender (based on World Health Organization BMI charts). Participant must have a minimum weight of 15 kg.\n* Participant must meet the International League of Associations for Rheumatology classification for 1 of the following categories and have, according to the investigator's judgment, moderately to severely active disease that is not adequately controlled with his\u002Fher current therapy.\n\n  * Rheumatoid factor (RF)-positive polyarthritis\n  * RF-negative polyarthritis\n  * Oligoarthritis\n  * Psoriatic arthritis\n  * Enthesis-related arthritis (ERA) Note: Historical Human leukocyte antigen B-27 (HLA-B27) results are considered appropriate for ERA diagnosis during screening.\n  * Systemic JIA with active arthritis without active systemic features, or with active systemic features that are stable in the prior 6 months of time of enrollment\n* Participant with intolerance or a history of inadequate response to at least one of the following medications for the treatment of JIA, administered for at least 12 weeks, based on current treatment guidelines: conventional synthetic disease-modifying antirheumatic drugs and biological disease-modifying antirheumatic drugs (including methotrexate) and non-steroidal anti-inflammatory drugs for ERA and psoriatic arthritis.\n* Female participants of childbearing potential (i.e. who have passed menarche) must have a negative highly sensitive urine pregnancy test.\n\nKey Exclusion Criteria:\n\n* Participant with persistent oligoarthritis.\n* Participant with undifferentiated arthritis.\n* Participant with any other any other rheumatic, inflammatory, or immunologic disease (e.g. inflammatory bowel disease, hypogammaglobulinemia, systemic lupus erythematosus, or uncontrolled uveitis).\n* Active infection that is clinically significant, as per judgment of the investigator.\n* Participant with a history of complicated herpes zoster infection (with multi-dermatomal, disseminated, ophthalmic, or central nervous system involvement).\n* Currently on any therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex, or atypical mycobacteria).\n\nNote: Other protocol defined Inclusion\u002F Exclusion criteria may apply.","ALL","8 Years","18 Years",{"count":155,"type":156},10,"ESTIMATED","INTERVENTIONAL",[159],"PHASE1","A Study to evaluate the pharmacokinetics, safety, and tolerability in paediatric population for treating juvenile idiopathic arthritis (JIA).",[162],"Juvenile Idiopathic Arthritis","2026-05-19",{"date":165,"type":166},"2026-05-22","ACTUAL",{"date":168,"type":166},"2024-05-13",{"date":170,"type":156},"2026-08",{"name":5,"class":6}]